Compounds > levofloxacin
Page last updated: 2024-09-04

levofloxacin and cci 15641

levofloxacin has been researched along with cci 15641 in 5 studies

Compound Research Comparison

Studies
(levofloxacin)		Trials
(levofloxacin)		Recent Studies (post-2010)
(levofloxacin)		Studies
(cci 15641)		Trials
(cci 15641)		Recent Studies (post-2010) (cci 15641)
4,3465812,209801

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Brown, SD; Critchley, IA; Jacobs, MR; Janjic, N; Tillotson, GS; Traczewski, MM1
Arhin, FF; Draghi, DC; Moeck, G; Parr, TR; Pillar, CM; Sahm, DF1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1

Other Studies

5 other study(ies) available for levofloxacin and cci 15641

ArticleYear
Cheminformatic models to predict binding affinities to human serum albumin.
    Journal of medicinal chemistry, 2001, Dec-06, Volume: 44, Issue:25

    Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids

2001
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Prevalence of serotype 19A Streptococcus pneumoniae among isolates from U.S. children in 2005-2006 and activity of faropenem.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:7

    Topics: Adolescent; Anti-Bacterial Agents; beta-Lactams; Child; Child, Preschool; Drug Resistance, Bacterial; Humans; Infant; Microbial Sensitivity Tests; Phenotype; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; United States

2008
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:11

    Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus faecium; Glycopeptides; Gram-Positive Bacteria; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus

2009
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013